Hims & Hers Health, Inc. Class A Common Stock (HIMS)
50.89
-3.07 (-5.69%)
NYSE · Last Trade: Sep 16th, 9:02 PM EDT
Detailed Quote
Previous Close
53.96
Open
54.32
Bid
50.35
Ask
50.40
Day's Range
48.69 - 54.34
52 Week Range
15.73 - 72.98
Volume
49,261,731
Market Cap
9.77B
PE Ratio (TTM)
64.42
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
27,232,726
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one thing is certain; after a year of tech-led mega caps setting new highs, investors have clearly shown an increased appetite for risk in the form of smaller, lesser known names.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) sent the company a warning letter regarding “false or misleading” claims about its compounded semaglutide products.
The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 55.7%, hitting $54 per share. This run-up might have investors contemplating their next move.
FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA rules.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the afternoon session after the stock extended its positive momentum as the company announced its expansion into the testosterone replacement therapy market.
Businesses with strong free cash flow tend to be more adaptable and resilient.
Some of these companies shine bright by using their cash wisely to strengthen their market positions.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the morning session after the stock's positive momentum continued as the company announced its expansion into the testosterone replacement therapy market by launching a new category in men's health.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.8% in the afternoon session after the company announced its long-awaited entry into the testosterone replacement therapy market.
According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.
Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services as weight-loss drug sales slow and investor interest grows.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new category in men’s health, offering access to innovative, affordable, and personalized treatment plans for low testosterone.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.9% in the morning session after it continued a rally from the previous day fueled by strong revenue guidance and supportive analyst actions.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
